Free Shipping on orders $25 or more!

Salivary Diagnostics for Early Detection of Cancer

A quick and painless diagnostic tool is set to transform the practice of dentistry and enhance the collaboration between dentists and physicians. PeriRx, LLC has developed a non-invasive diagnostic test that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management. PeriRx's product, SaliMark™ OSCC, is the first commercial saliva test for the early detection of Oral Squamous Cell Carcinoma.

Over 43,000 new cases of oral cancer were detected in the United States last year. The vast majority of these cases are classified as Oral Squamous Cell Carcinoma (OSCC). According to the Oral Cancer Foundation, "When found at early stages of development, oral cancers have an 80 to 90 % survival rate." Unfortunately, the majority of cases are found at advanced stages, and this accounts for the very high death rate of about 43% at five years from diagnosis. Those who do survive a late stage diagnosis of OSCC can face a lifetime of serious complications, including speaking, breathing and eating difficulties along with physical disfigurement.

Saliva can be easily obtained by a dentist, hygienist, physician or nurse to evaluate biomarkers for various diseases, removing the need for invasive procedures with needles. Currently, salivary biomarkers have been identified to aid in early diagnosis of OSCC. This allows patients with suspicious oral lesions to be categorized into low or higher risk groups to help determine when further evaluation by a specialist is necessary and to aid in the decision for a biopsy.

PeriRx is currently working on salivary diagnostic tests for the early detection of additional diseases, such as lung cancer, diabetes, Sjogren's Syndrome, and periodontal disease. Sign up for advance notice of exciting new developments and educational opportunities regarding ground-breaking salivary diagnostic technology at http://perirx.com/newsletter-signup/

Leave a comment

Name .
.
Message .